573097
STAT3抑制剂III，WP1066
STAT3 Inhibitor III, WP1066, CAS 857064-38-1, is a cell-permeable AG490 tyrphostin analog that acts as a STAT3 pathway inhibitor. A potent anti-tumor agent.
别名:
STAT3抑制剂III，WP1066
质量水平
方案
≥97% (HPLC)
表单
solid
制造商/商品名称
Calbiochem®
储存条件
OK to freeze
protect from light
颜色
off-white
溶解性
DMSO: 10 mg/mL
ethanol: 5 mg/mL
运输
ambient
储存温度
2-8°C
SMILES字符串
Brc1nc(ccc1)\C=C(\C(=O)N[C@@H](C)c2ccccc2)/C#N
InChI
1S/C17H14BrN3O/c1-12(13-6-3-2-4-7-13)20-17(22)14(11-19)10-15-8-5-9-16(18)21-15/h2-10,12H,1H3,(H,20,22)/b14-10+/t12-/m0/s1
InChI key
VFUAJMPDXIRPKO-LQELWAHVSA-N
一般描述
一种细胞渗透性AG 490（目录号658401）酪磷蛋白类似物，在体外培养（使用U87-MG和U373-MG进行生存能力试验时，IC50分别为5.6和3.7 µM；在10 µM时对非肿瘤NHA无抑制作用）和小鼠体内培养中，作为有效的STAT3途径抑制剂和比AG 490更有效的抗肿瘤剂抑制恶性胶质瘤生长。显示在小鼠体内能跨越血脑屏障。也可提供InSolution格式（目录号573129）。
一种细胞渗透性AG 490（目录号658401）酪磷蛋白类似物，在体外培养（使用U87-MG和U373-MG进行生存能力试验时，IC50分别为5.6和3.7 µM；在10 µM时对非肿瘤NHA无抑制作用）和小鼠体内培养中，作为有效的STAT3途径抑制剂和比AG 490更有效的抗肿瘤剂抑制恶性胶质瘤生长。显示在小鼠体内能跨越血脑屏障。
生化/生理作用
主靶
STAT3通路
STAT3通路
产物不与ATP竞争。
可逆：否
细胞可渗透性：是
靶标IC50：分别为5.6和3.7 µM，在使用U87-MG和U373-MG的活性试验中，抑制恶性胶质瘤生长
包装
用惰性气体包装
制备说明
复溶后，等分并冷冻保存（-20°C）。贮备溶液在-20°C下可稳定保存至多6个月。
其他说明
Iwamaru, A., et al. 2007.Oncogene,26, 2435.
法律信息
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
免责声明
毒性：刺激性（B）
储存分类代码
11 - Combustible Solids
WGK
WGK 2
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Alicia Haydo et al.
EMBO reports, 24(12), e56964-e56964 (2023-11-08)
Glioblastoma is a very aggressive tumor and represents the most common primary brain malignancy. Key characteristics include its high resistance against conventional treatments, such as radio- and chemotherapy and its diffuse tissue infiltration, preventing complete surgical resection. The analysis of
In-Hye Ham et al.
International journal of oncology, 61(1) (2022-05-28)
The present study aimed to investigate whether the Janus‑activated kinase (JAK)/signal transducer and activator of transcription 3 (STAT3) signaling pathway is a critical mechanism underlying the cancer‑associated fibroblast (CAF)‑induced chemoresistance of gastric cancer (GC). In addition, the present study tried to
Meng Chi et al.
Annals of translational medicine, 8(8), 531-531 (2020-05-16)
Dexmedetomidine (DEX), a highly selective α2-adrenergic receptor agonist, has been reported to increase the malignancy of breast cancer cells in vitro and stimulate tumor growth in mice. Transmembrane protease serine 2 (TMPRSS2) demonstrates proteolytic activity, resulting in degradation of the
Eun-Ji Lim et al.
Cell death & disease, 13(4), 417-417 (2022-04-30)
Colorectal cancer (CRC) has a 5-year survival rate of <10%, as it can metastasize to the lungs and liver. Anticancer drugs and targeted therapies used to treat metastatic colorectal cancer have insufficient therapeutic efficacy and are associated with complications. Therefore
Ahmad Sharanek et al.
Cell reports, 36(9), 109647-109647 (2021-09-02)
Brain tumor stem cells (BTSCs) and intratumoral heterogeneity represent major challenges in glioblastoma therapy. Here, we report that the LGALS1 gene, encoding the carbohydrate binding protein, galectin1, is a key regulator of BTSCs and glioblastoma resistance to therapy. Genetic deletion
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持